Café

© 2026 Longbridge｜Terms of Service Privacy Policy

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

StockTitan

May 21, 2026 at 01:40 PM

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 | ZNTL Stock News

Login to unlock227characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

Apr 20, 2026 at 06:34 PMEli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy …
Apr 16, 2026 at 11:12 AMUS Stocks Hit New Highs, Retail Investors Miss Out en masse: Tom Lee Says Next Rally Will Be Led by Them
Apr 13, 2026 at 01:07 AMU.S. Stocks Face a "Final Battle" as Hormuz Outcome Decides the Game: The Rash Never Win, the Patient Prevail
Apr 7, 2026 at 10:32 PMReminder: Key events to watch intraday (all times Beijing Time)

Related Stocks

ZeZentalis Pharma

USZNTL

0.00%

iShares Biotechnology ETF

USIBB

SPDR S&P Biotech

USXBI

LongbridgeAI